Spyre Therapeutics Prices Upsized $403M Public Offering to Fund Clinical Pipeline Advancement

summarizeSummary

Spyre Therapeutics has priced an upsized public offering of 6.5 million shares at $62.00 each, raising approximately $403 million to fund the advancement of its clinical pipeline following recent positive trial data.

check_boxKey Events

• Upsized Public Offering Priced

  Spyre Therapeutics priced an underwritten public offering of 6,500,000 shares of common stock at $62.00 per share, generating approximately $403 million in gross proceeds. Underwriters have a 30-day option to purchase an additional 975,000 shares.

• Strategic Capital Raise for Pipeline

  The proceeds will be used to advance the company's programs in inflammatory bowel disease (IBD) and rheumatic diseases, including funding preclinical studies, clinical trials, manufacturing, and Phase 3 readiness activities. This follows the announcement of highly positive Phase 2 data for SPY001 on April 13, 2026.

• ATM Program Terminated

  In connection with this offering, the company suspended and terminated its At-The-Market (ATM) offering prospectus, indicating a shift from a flexible, continuous offering to a larger, fixed-price capital infusion.

auto_awesomeAnalysis

This filing finalizes the terms and pricing of the upsized public offering, which was initially proposed on April 13, 2026, following the announcement of highly positive Phase 2 clinical trial data for SPY001. The offering of 6.5 million shares at $62.00 per share will raise approximately $403 million before expenses, with potential for an additional $60.45 million if the underwriters' option is fully exercised. This capital raise, priced at a modest discount to recent trading, significantly strengthens the company's financial position, providing substantial funding for the advancement of its IBD and rheumatic disease programs, including preclinical studies, clinical trials, manufacturing, and Phase 3 readiness activities. The company also terminated its At-The-Market (ATM) offering prospectus in conjunction with this fixed-price offering, indicating a strategic shift to a larger, one-time capital infusion.